netFormulary Sheffield Teaching Hospitals NHS
NHS Foundation Trust  
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Chapter Links...
 Details...
08.03.04.02  Expand sub section  Gonadorelin analogues and gonadotrophin-releasing hormone antagonists
 note   
08.03.04.02  Expand sub section  Gonadorelin analogues and gonadotrophin-releasing hormone antagonists
08.03.04.02  Expand sub section  Anti-androgens
Abiraterone Acetate (Zytiga®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
tablets

Red traffic light classification in relation to TA259 
Link  NICE guidance - For Castration-Resistant Metastatic Prostate Cancer Previously Treated With A Docetaxel-Containing Regimen
Link  NICE guidance - Treatment of Metastatic Hormone-Relapsed Prostate Cancer Before Chemotherapy is Indicated
   
Bicalutamide (Casodex®)
View adult BNF View SPC online
Formulary
Amber
tablets 
Link  Hormonal Management of Prostatic Cancer SCP
   
Cyproterone Acetate
View adult BNF View SPC online
Formulary
Amber
tablets 
Link  Hormonal Management of Prostatic Cancer SCP
   
Enzalutamide (Xtandi®)
View adult BNF View SPC online
Restricted Drug Restricted
Red
High Cost Medicine

capsules

 
Link  NICE guidance - For Treatment of Metastatic Hormone-Relapsed Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Link  Treatment of Metastatic Hormone-Relapsed Prostate Cancer Before Chemotherapy is Indicated
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Definition Certain drugs that are initiated by a specialist but are suitable for GPs to continue ongoing prescribing. The specialist should provide the GP with necessary information and support in order for treatment to be managed safely in primary care. Shared care protocols (SCP) or prescribing guidelines may be available. 1. Requiring specialist assessment to enable patient selection. 2. Requiring a period of monitoring by a specialist. 3. The initial prescription should normally be issued by the specialist unless the agreed SCP states otherwise.  

Black

Definition A drug which should not be initiated in Sheffield unless exceptional circumstances apply to the individual concerned and an Individual Funding Request (IFR) has been agreed by NHS Sheffield. The drug should not be withdrawn from patients already established on treatment but other treatment options should be considered at routine review. Criteria 1. There is a clear Yorkshire and Humber Specialised Commissioning Group decision to not routinely fund usage of the drug. 2. There is a NICE recommendation that the drug should not be prescribed on the NHS for the condition specified. 3. A drug requiring specific commissioning arrangements to be clarified and put in place before prescribing can take place.  

Green

Drugs for which GPs should take full responsibility for initiating and ongoing prescribing.   

Red

Definition Prescribing and ongoing supply is normally undertaken by a consultant or other physician within a secondary care service. In some exceptional circumstances and following discussion between primary and secondary care, GPs may consider it to be in the patient’s best interest for drugs in the Red section of the traffic light scheme to be prescribed in primary care. Red traffic light drugs meet one or more of the following criteria: 1. Require specialist assessment to enable patient selection, initiation, ongoing treatment and monitoring of efficacy, toxicity or adverse effects. 2. Specifically designated as “hospital only “either by product licence or by DH 3. Hospital initiated clinical trial materials used in accordance with the trial protocol 4. Not listed in the current BNF or BNF (C). 5. Being used to treat a condition that is not suitable for primary care prescribing because of disease specific requirements, complexity or defined commissioning arrangements.  

netFormulary